• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

byMinjee Kim
November 30, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. At 24 months, treatment success rate was numerically greater in the shorter-regimen group versus conventional therapy, satisfying the noninferiority criteria.

2. Time to culture conversion in solid media was quicker in the intervention group compared to conventional therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Multidrug-resistant tuberculosis (MDR-TB) is an infection by Mycobacterium tuberculosis that is resistant to isoniazid and rifampicin. Conventional therapy for MDR-TB includes at least 20 months of anti-TB drugs with an injectable for 8 months. However, given the extensive treatment period, adherence to the treatment regimen can be variable. New all-oral drug regimens have been developed that may shorten treatment duration while having comparable efficacy. This randomized trial aimed to investigate the safety and efficacy of all-oral regimen (delamanid, linezolid, levofloxacin, and pyrazinamide) versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis. The primary outcome was treatment success at 24 months while key secondary outcome included time to sputum culture conversion. According to study results, the shorter, all-oral treatment group was noninferior to conventional therapy after 24-months of follow-up. This study was strengthened by a large sample size with individuals of all ages, thus increasing its credibility.

Click to read the study in The Lancet

Relevant Reading: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

RELATED REPORTS

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

In-depth [randomized-controlled trial]: Between Mar 4, 2016, and Sept 14, 2019, 443 patients were screened for eligibility at 12 hospitals in South Korea. Included were those aged 19-85 years with confirmed multidrug-resistant tuberculosis. The intervention group received 9-months of delamanid, linezolid, levofloxacin, and pyrazinamide, while the conventional therapy group received 20-24 months of treatment according to the 2014 WHO and 2014 South Korea guidelines for treatment of MDR-TB. Altogether, 168 patients (89 in control group and 79 in shorter-regimen group) were included in the intention-to-treat analysis. Median age of patients was 47 years, and the majority were men (69%). The primary outcome of treatment success at 24 months from baseline was numerically greater in the intervention group (54 of 72, 75%) than in the control group (60 of 85, 71%; between-group difference 4.4% [97.5% one-sided CI 9.5% to ∞, satisfying the non-inferiority criteria). In solid media, the time to culture conversion was significantly shorter in the 9-month treatment group compared to the conventional 20–24-month treatment group (19 days vs. 25 days, respectively; p=0.036). Overall, findings from this study suggest that 9-month treatment with delamanid, linezolid, levofloxacin, and pyrazinamide may be effective in patients with fluoroquinolone-sensitive multidrug-resistant TB.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antituberculosis treatmentdelamaniddrug-resistant tuberculosislevofloxacinlinezolidmultidrug-resistant tuberculosismultidrug-resistant tuberculosis (MDR-TB)mycobacterium tuberculosispyrazinamidetbTB Skin Testtuberculosis
Previous Post

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

Next Post

Self-monitoring of physical activity may be enhanced through additional interventions

RelatedReports

Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Chronic Disease

Oral BPaLM regimen is noninferior to standard of care for rifampin-resistant tuberculosis

January 4, 2023
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Chronic Disease

Two bedaquiline-containing regimens had superior efficacy and safety profiles for treatment of rifampin-resistant tuberculosis

December 7, 2022
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

All-oral regimen with delamanid, linezolid, levofloxacin, and pyrazinamide is effective for fluoroquinolone-sensitive multidrug-resistant tuberculosis

November 8, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

Bedaquiline-pretomanid-linezolid regimen is effective for treating drug-resistant tuberculosis

September 1, 2022
Next Post
Adolescents’ muscle strength associated with lower cardiometabolic risk

Self-monitoring of physical activity may be enhanced through additional interventions

Low-dose ketamine may reduce shivering following spinal anesthesia

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Monoclonal antibody treatment does not improve outcomes in COVID-19-positive pregnant patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options